Sun Pharma paid $11.75 billion for Organon, the largest biopharma acquisition of 2026 and the biggest deal any Indian drugmaker has ever announced.
Organon’s 2025 sales matched Sun’s own last year. That means this isn’t a bolt-on: Sun is doubling its revenue base in a single deal. The transaction makes Sun the No. 7 biosimilar seller globally, a ranking it couldn’t have reached through organic growth alone. Organon’s skin cream Vtama also fits Sun’s specialty dermatology business, giving the buyer two commercial rationales in one deal: biosimilar scale and a dermatology plug-in.
What does the buyer actually get? A biosimilar portfolio that vaults Sun into the global top 10, plus Vtama, a commercial-stage dermatology asset Sun can run through its existing skin business without building new distribution infrastructure. The Vtama piece is the cleaner fit: Sun already has a specialty dermatology operation, and a skin cream drops straight into that channel. The biosimilar side is larger but carries more competitive pressure.
No per-share price was disclosed in the announcement. The deal’s financing structure hasn’t been released either. At $11.75 billion, this is the largest check ever written by an Indian pharma company, and the deal’s value depends on Organon’s biosimilar business holding its market position. If biosimilar pricing comes under pressure, Sun’s paid a full price for assets that could deliver shrinking margins.
No close date has been set.
Diana Kowalski